skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Bisoprolol in the treatment of chronic heart failure

(2546) Views  (529) Full article downloads

Authors: Pascal de Groote, Pierre-Vladimir Ennezat, Fréderic Mouquet

Published Date October 2007 Volume 2007:3(4) Pages 431 - 439
DOI: http://dx.doi.org/10.2147/VHRM.S

Pascal de Groote1, Pierre-Vladimir Ennezat2, Fréderic Mouquet1

1Service de Cardiologie C, 2Service des soins intensifs cardiologiques, Hôpital Cardiologique, Centre Hospitalier Régional et Universitaire de Lille, France

Abstract: Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients. The CIBIS trial enrolled 641 patients and demonstrated the good tolerability of bisoprolol in a large CHF population, without evidence for any harmful effect. The CIBIS-II study was the first large randomized, double-blind, placebo-controlled study demonstrating in 2647 patients a dramatic reduction in mortality with a beta-blocking agent in CHF patients. CIBIS-III demonstrated in 1010 patients the equivalence of 2 different therapeutic strategies in de novo CHF patients. There was no difference in morbidity and mortality between sub-groups of patients receiving first bisoprolol or enalapril. These three trials also demonstrated the good tolerability of bisoprolol fumarate. Other studies were either limited in number of patients or not randomized. However, these studies confirmed the good tolerability of bisoprolol in CHF patients, even in elderly population. Bisoprolol fumarate is a selective beta-1 receptor blocker that significantly reduced morbidity and mortality in stable CHF patients. Bisoprolol is well tolerated with few significant side effects in different large trials.

Keywords: bisoprolol, chronic heart failure, beta-blocker








Readers of this article also read:

Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors
Immediate and six months clinical and angiographic results of intracoronary paclitaxel-coated stent implantation – the Meo:DrugStar-1 study
Peripheral artery disease: potential role of ACE-inhibitor therapy
Primary care assessment instruments for patients at risk of, or with, persistent pain: opportunistic findings from a systematic literature review
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
Optimizing weight control in diabetes: antidiabetic drug selection
Novel drug-eluting stents in the treatment of de novo coronary lesions
Editorial
A case of recurrent bloody tears
Primary care for diabetes mellitus: perspective from older patients
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University